Bhagirath Dholaria, MD

Innovative trials with focus on #myeloma cure!! @VUMCDiscoveries @VUMChealth

@DeceraClinEdu @MichaelDJain He is the best! A voice of clarify and reason among the fuzzy data and opinions. 🙏

🔥 Featured Faculty Spotlight: @MichaelDJain As we prepare for #ASH2025, we’re honored to highlight Dr. Michael D. Jain, a leading expert in cellular immunotherapy whose work continues to shape the future of lymphoma treatment. Dr. Jain brings deep expertise in CAR T-cell therapy, translating emerging evidence into practical, patient-centered guidance for clinicians navigating this rapidly evolving landscape. Join us in Orlando for our Hematology Symposia!! It's not too late to register for in-person or online attendance: bit.ly/4nyUrXZ #HematologySymposia #DeceraClinicalEducation

All CoMMit active trials and past research is now in one place. Learn more about and support our work. commitmyelomatrials.org

@JanakiramMurali @mmejia91 @SusanBal9 not surprised. We have not found any benefit of dex or toci prophy in ICANS prevention either with CD19 CAR T. Need mechanistic studies first to define pathophysio of delayed NT before we start planning interventions.

@mmejia91 @SusanBal9 yes Mateo lets meet at ASH

Interesting abstract on suppressive dexamethasone, ALC and delayed neurotox -single-center retrospective, N=56, -From the results no effect of suppressive dex for ALC >3 on delayed neurotox. Need to consider different strategies. a/w publication ALC highly predictive meetings-api.hematology.org/api/abstract/v…

Co-chaired by 🤩@Sonyareid07 #breastcancer and @DholariaMD #leukemia @VUMCDiscoveries

@DrFredLocke @MoffittNews @hiendliu1 @MichaelDJain @freemanlciaraMD @nishihori Congratulations on this milestone🙌

From our first transplant in 1989 to our 10,000th today 🎉 We celebrated with our faculty, nurses, pharmacists & APPs (photo: faculty), with deepest gratitude to the patients & families who entrust us with their care. @MoffittNews

@RahulBanerjeeMD @End_myeloma @bdermanmd @Rfonsi1 As our therapies get better at achieving <10e-6, we will have enough events/power to test these hypothesis. Clearly 2+HRCA is the group where we need better discrimination before de-escalation.

@End_myeloma @bdermanmd @Rfonsi1 Very well stated as always!! Although you all can guess what I would say... If you had to draw a line throuh Dara/V/R/d to delineate the drugs that actually matter, I know where I'd draw mine 🤣

The S-MRD-5 vs. S-MRD-6 created some good questions and surprised some. It comes down to the difference between "what produces the best classifying model" and "what is the best result to have". They are often different things. To use an analogy, and still stay in MM: B2M 1/x

@ChenyuLinMD @VincentRK @RahulBanerjeeMD @Rfonsi1 @TomBmt133 From my limited experience, it seems inferior control arms given rapidly expanding access to CAR and bispecifics. By the time, we open a study, SOC is no longer appropriate for the given population.

@VincentRK @RahulBanerjeeMD @Rfonsi1 @TomBmt133 Why do you think there are low accruals in the US? Is it just regulatory burden or are there other issues specific to the US clinical trial environment?

So the belantamab ODAC is on. Personally I hope the belantamab is approved for relapsed myeloma. It has many advantages and there is a unique need for the drug in relapsed refractory myeloma. If available we will have an important option to tackle very difficult situations for which other options are not possible or far more riskier. See thread. Yes there is a problem with belantamab dosing. But there is no question the drug works and with appropriate modification of dose frequency we won’t have the type of eye toxicity that’s been seen in the phase III trials. Note that we did not have the best dose for many myeloma drugs when they were first approved. Many are just not used in the dose that they were approved at: bortezomib, pomalidomide, carfilzomib, even bispecifics. But there is no question lives were saved due to early approval of these drugs even though the dosing was not ideal in regulatory trials of these drugs. It’s a balance between the risk of approving an effective life saving drug tested with a less than ideal dose in the regulatory phase III versus the risk of delaying approval and access by a very long time to find the best dose. In the case of belantamab, that would be years. In clinical practice we are able to modify dosing to the extent that’s not possible in a clinical trial. We also have learnt a lot since the regulatory trials already that help with optimizing dosing. So I hope for the best because in my opinion myeloma patients with relapsed refractory disease need belantamab available as an option.

Here is our June @VUMCDiscoveries #youngadultcancer newsletter. #earlyonset #cancer #nationalcancersurvivorsmonth Link: t.e2ma.net/webview/eaqr7l… @EOAYACoP #AYA #tooyoung #patientcare #advocacy @DholariaMD @Sonyareid07 @drholowatyj @jordanberlin5 @JJSingleton1 @ARosen380

Patients with standard risk MM treated with QUADs + ASCT, achieving S-MRD negativity and stopping therapy have <10% risk of progression or MRD resurgence in 4 years!

Join us for the upcoming @TheIACH for Nurses: Outpatient Bi-Specific Therapy Clinic with Leslie Mader & Bhagirathbhai Dholaria 🗓️Thursday, May 8 2025 ⏲️6pm CET Register for FREE ⬇️⬇️ us06web.zoom.us/webinar/regist… @lesliemader @DholariaMD @Mohty_EBMT

@AshKishtagari @foghorntx @CCR_AACR @VUMChealth Next step ?combo w VEN/HMA

@DholariaMD @foghorntx @CCR_AACR @VUMChealth Thank you Bhagi!

Excited to share the results @foghorntx FH286 published in @CCR_AACR. My first clinical trial! Grateful for my my team @VUMChealth and patients who made this possible! A Phase 1 Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients With Advanced Myeloid Malignancies aacrjournals.org/clincancerres/…

Open and enrolling @VUMCDiscoveries @BipinSavani @EdenBiltibo

@RahulBanerjeeMD @HiraSMian Mostly true in USA at this point. There may be few new candidates on horizon.

@HiraSMian I think primarily just P-BCMA-ALLO1 and the Caribou Camouflage one! I think the others are no longer in commercial development - more or less accurate, @DholariaMD ? Certainly there’s a role for these if infectious risks lower, especially if they work post-failure of auto CAR!

#DAVAWhistler great presentation by Ken Shain about allo-CARs in #MMsm myeloma. The list of abandoned candidates is almost as long as the number of patients treated on the remaining ones, but these do look quite promising! Easy to give, not as much lymphodepletion as before…

@bdermanmd @End_myeloma I have noticed this pattern too in last 3-4 yrs. Many requiring steroids. Also, 3 cases of severe auto-GVHD (bx proven) involving skin+ gut. Not sure if there is a pattern here.

Wondering @End_myeloma if you looked at this in your pooled analysis sciencedirect.com/science/articl…

13% incidence of engraftment syndrome. Seems odd that the median cd34+ cell dose was only 1.75x10^6/kg (we aim for 3-5 & always >2). Dara was used only for patients who needed add’l disease reduction before transplant. Despite these peculiarities, we have noted more ES in recent years which coincides with quad induction. Would be really interesting to know if patients collected in the quad era who defer transplant have higher incidence of ES when they proceed to transplant later.

@MediHumdani donor original T LGL. I have a few who recovered ANC with FK taper, rest needed low dose steroid/MTX.

❓Quiz ⏲️⏲️: 68yr old MDS patient day +167 post ptCY-based matched Allo HCT. No #GvHD - On 0.5mg of tacrolimus - CBC showed WBC of 2.0; platelets 204. ANC 600/uL - On exam no adenopathy - T-cell chimerism fully donor - PB flow shown below Diagnosis & Rx?? #bmtsm Allo 🦪

📢 Don't miss the next @TheIACH post #ASH24 webinar: the Most Important Cellular Therapy Studies 🎙️ Speaker: Dr. Bhagirathbhai Dholaria 🗓️ Friday, January 17, 2025 🕔 5 PM CET 🎟️ Register for FREE: 👉 bit.ly/3DSZHni @DholariaMD @Mohty_EBMT

@MediHumdani Bi-specifics are currently at a stage where CAR T therapy was in early 2000. They will outpace CAR given ease of logistics, and combinations.

Safety and Efficacy of Glofitamab for DLBCL in RW. It works, but like nearly all drugs, works less well in the streets #lymsm ashpublications.org/bloodadvances/…

Historic and exemplary! Congratulations to Gukesh D on his remarkable accomplishment. This is the result of his unparalleled talent, hard work and unwavering determination. His triumph has not only etched his name in the annals of chess history but has also inspired millions of young minds to dream big and pursue excellence. My best wishes for his future endeavours. @DGukesh